216 related articles for article (PubMed ID: 21844884)
1. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.
Wheeler HE; Gamazon ER; Stark AL; O'Donnell PH; Gorsic LK; Huang RS; Cox NJ; Dolan ME
Pharmacogenomics J; 2013 Feb; 13(1):35-43. PubMed ID: 21844884
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.
Wheeler HE; Gorsic LK; Welsh M; Stark AL; Gamazon ER; Cox NJ; Dolan ME
PLoS One; 2011; 6(7):e21920. PubMed ID: 21755009
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of resistance and toxicity associated with platinating agents.
Rabik CA; Dolan ME
Cancer Treat Rev; 2007 Feb; 33(1):9-23. PubMed ID: 17084534
[TBL] [Abstract][Full Text] [Related]
4. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.
Li R; Kim D; Wheeler HE; Dudek SM; Dolan ME; Ritchie MD
Pharmacogenomics J; 2019 Apr; 19(2):178-190. PubMed ID: 29795408
[TBL] [Abstract][Full Text] [Related]
5. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
O'Donnell PH; Gamazon E; Zhang W; Stark AL; Kistner-Griffin EO; Stephanie Huang R; Eileen Dolan M
Pharmacogenet Genomics; 2010 May; 20(5):327-37. PubMed ID: 20393316
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
Tan XL; Moyer AM; Fridley BL; Schaid DJ; Niu N; Batzler AJ; Jenkins GD; Abo RP; Li L; Cunningham JM; Sun Z; Yang P; Wang L
Clin Cancer Res; 2011 Sep; 17(17):5801-11. PubMed ID: 21775533
[TBL] [Abstract][Full Text] [Related]
7. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
8. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity.
Gamazon ER; Im HK; O'Donnell PH; Ziliak D; Stark AL; Cox NJ; Dolan ME; Huang RS
Mol Cancer Ther; 2011 Mar; 10(3):472-80. PubMed ID: 21252287
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
13. [Platinum antitumor complexes].
Bonetti A; Giuliani J; Muggia F
Recenti Prog Med; 2015 Dec; 106(12):618-28. PubMed ID: 26780071
[TBL] [Abstract][Full Text] [Related]
14. [Tolerance profile of platinum compounds].
Cascinu S; Munaó S; Mare M; Amadio P; Crucitta E; Picone G
Tumori; 2000; 86(3 Suppl):S54-5. PubMed ID: 10969619
[No Abstract] [Full Text] [Related]
15. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
16. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.
Gallagher DJ; Vijai J; Hamilton RJ; Ostrovnaya I; Iyer G; Garcia-Grossman IR; Kim PH; Przybylo JA; Alanee S; Riches JC; Regazzi AM; Milowsky MI; Offit K; Bajorin DF
Ann Oncol; 2013 Sep; 24(9):2414-21. PubMed ID: 23897706
[TBL] [Abstract][Full Text] [Related]
17. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy.
Asai Y; Eslami A; van Ginkel CD; Akhabir L; Wan M; Ellis G; Ben-Shoshan M; Martino D; Ferreira MA; Allen K; Mazer B; de Groot H; de Jong NW; Gerth van Wijk RN; Dubois AEJ; Chin R; Cheuk S; Hoffman J; Jorgensen E; Witte JS; Melles RB; Hong X; Wang X; Hui J; Musk AWB; Hunter M; James AL; Koppelman GH; Sandford AJ; Clarke AE; Daley D
J Allergy Clin Immunol; 2018 Mar; 141(3):991-1001. PubMed ID: 29030101
[TBL] [Abstract][Full Text] [Related]
19. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
Adams M; Kerby IJ; Rocker I; Evans A; Johansen K; Franks CR
Acta Oncol; 1989; 28(1):57-60. PubMed ID: 2650722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
